dianosic
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
165 200 2,636Activities
Technologies
Entity types
Location
8 Pl. de L Hôpital, 67000 Strasbourg, France
Strasbourg
France
Employees
Scale: 11-50
Estimated: 14
Engaged corporates
22
4 14Added in Motherbase
5 years, 1 month ago
deeptech Value proposition
"Smartly designed for you"
Dianosic ambitions to become a leading company in solving challenges in patient’s adherence to medication. We provide an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases.
Dianosic aims to fight against debilitating chronic diseases that affect millions of people. Our first focus is on chronic allergic rhinitis and chronic rhinosinusitis. Currently, 85% of allergic rhinitis patients are not compliant with their treatment. Furthermore, 20% to 25% of patients do not respond to first-line treatments. These medical challenges significantly impact patient’s quality of life.
We closely collaborate with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery. Our multidisciplinary team works hand in hand with them in order to design solutions that change physicians’ experience and offer patients minimally invasive and non-surgical options.
Dianosic develops ARIS, a unique platform that benefits from proprietary drug-eluting, long-term resorbable polymer. Our unique concept is meant to deliver patient centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use and patient adherence to treatment. Click here to learn more about our solutions: https://bit.ly/3Tnagog
📞 For more information, please contact us via LinkedIn private message, by mail (contact@dianosic.com) or phone (+33 1 44 04 45 80).
ENT, combination devices, drug-device combination, biotech, respiratory, Allergic rhinitis, Sinusitis, and Nose to brainOriginal language
"Smartly designed for you"
Dianosic ambitions to become a leading company in solving challenges in patient’s adherence to medication. We provide an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases.
Dianosic aims to fight against debilitating chronic diseases that affect millions of people. Our first focus is on chronic allergic rhinitis and chronic rhinosinusitis. Currently, 85% of allergic rhinitis patients are not compliant with their treatment. Furthermore, 20% to 25% of patients do not respond to first-line treatments. These medical challenges significantly impact patient’s quality of life.
We closely collaborate with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery. Our multidisciplinary team works hand in hand with them in order to design solutions that change physicians’ experience and offer patients minimally invasive and non-surgical options.
Dianosic develops ARIS, a unique platform that benefits from proprietary drug-eluting, long-term resorbable polymer. Our unique concept is meant to deliver patient centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use and patient adherence to treatment. Click here to learn more about our solutions: https://bit.ly/3Tnagog
📞 For more information, please contact us via LinkedIn private message, by mail (contact@dianosic.com) or phone (+33 1 44 04 45 80).
Home - Dianosic
https://www.dianosic.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Inria Research, Research Services | Inria Research, Research Services | Other 25 Sep 2024 | | |
 Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Ville et Eurométropole de Strasbourg National and local authorities, Government Administration, French metropolis | Other 25 Sep 2024 | | |
 | Forces Françaises de l'Industrie | Other 19 Mar 2024 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 22 Mar 2024 | | |
 Crédit Mutuel Bank, Banking | Crédit Mutuel Bank, Banking | Other 12 Feb 2024 | | |
 Starquest Venture Capital and Private Equity Principals | Starquest Venture Capital and Private Equity Principals | Other 12 Feb 2024 | | |
 Xplore Venture Capital and Private Equity Principals | Xplore Venture Capital and Private Equity Principals | Other 12 Feb 2024 | | |
 Caisse d’Epargne Banking | Caisse d’Epargne Banking | Other 8 Mar 2024 | | |
 WiSEED Crowdfunding, Financial Services | WiSEED Crowdfunding, Financial Services | Other 12 Oct 2024 | | |
 SEMIA Startup accelerator & VC, Business Consulting and Services | SEMIA Startup accelerator & VC, Business Consulting and Services | Other 19 Jan 2018 16 Jun 2024 | | |